UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.

A genomic analysis of poorly differentiated neuroendocrine tumors from primary lung and gastrointestinal sites underscores the diversity of these tumors and the evolving need to move toward precision medicine when it comes to treating patients with these malignancies.

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

Hope S. Rugo, MD, discusses the recent findings with MYL-1401O and the role of biosimilars in patients with HER2-positive breast cancer.

Hope Rugo, MD, discusses how to balance the benefits and risks of neratinib, as well as unanswered questions regarding ExteNET, in patients with HER2-positive breast cancer.

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).

This year's approval of radium-223 chloride (Xofigo) continues the 4-year run of important new prostate cancer drugs, and Matthew Cooperberg thinks the run will continue over the next few years.

Breast Oncology Director leads effort to honor luminaries who have helped patients survive

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

The key to advancements in chemotherapy treatment for patients with metastatic breast cancer most likely will come through a better understanding of their underlying tumor biology.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.